DYSIS Medical appoints Rob Cascella as Chairman

Edinburgh – 7 January 2014 − DYSIS Medical Ltd, a medical devices company active within Women’s Health, today announces that Robert Cascella has joined as Chairman of the board of directors of the Company effective January 2014. His appointment further strengthens the board following a year of investment and growth in 2013.

Mr. Cascella was previously Chief Executive Officer and President of Hologic Inc., a leading manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products for Women’s Healthcare, between 2003 and 2013. He has over 30 years of senior management, operational and finance experience. Prior to Hologic, Mr. Cascella served as Managing Partner of CFG Capital LLC, an investment banking firm specialising in healthcare and was the Chief Operating Officer and Vice President of Finance at NeoVision Corporation, a developer of 3D ultrasound technology used for real-time guidance of interventional breast procedures.

Alastair Atkinson, CEO of DYSIS Medical, said: “We welcome Robert as Chairman. His industry knowledge, market and technology expertise and extensive connections in the Women’s Healthcare industry add substantial value to our team. I look forward to working with him to move DYSIS into the next stage of growth and expansion.

“I look forward to working with Alastair and the team on the commercialisation strategy of a technology capable of significantly improving upon the diagnostic protocols for cervical disease,” Mr. Cascella added. “DYSIS has the unique opportunity to increase the effectiveness of the current standard of care in developed markets, while potentially addressing an unmet healthcare need in emerging markets, where the diagnosis and treatment of cervical disease remains woefully inadequate.”

DYSIS Medical, a medical devices company active within Women’s Health, has developed an advanced cervical scan which, in addition to performing traditional colposcopy examinations, uses dynamic spectral imaging to scan, quantify and map the cervix.

Ends

For more information, please contact:

DYSIS Medical Ltd                                        Tel: +44 (0)1506 592159

Alastair Atkinson, CEO

College Hill (PR for DYSIS Medical)           Tel: +44 (0)20 7457 2020

Katherine Lynch / Gemma Howe

Email: dysis@collegehill.com

Notes to Editors

DYSIS Medical Ltd

DYSIS Medical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com

The DYSIS product employs advanced photonics and computer assistance to quantify and map the cervix during the aceto-whitening process. The product is CE marked and commercially available in Europe. It is also cleared to market in the USA by the FDA under the 510(k) programme as a digital colposcope designed to image the cervix and lower genital tract under illumination and magnification. Colposcopy is indicated for women with an abnormal Pap smear in order to affirm normality or detect abnormal appearances consistent with neoplasia, often with directed biopsy.